Therapeutic vaccination using patient-derived immune cells for lung cancer treatment
Official title: Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
Funded at University of California Los Angeles · NIH-10893578 · Data updated 2026-11-12
This study is testing a new type of vaccine for people with non-small cell lung cancer that uses their own immune cells to help their body fight the cancer better, focusing on specific markers in their tumors to create a personalized treatment that could lead to improved results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 25, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $209,850 |
| NIH project number | 5R21CA277172-02 |
| Project ID | NIH-10893578 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific genetic markers related to HLA-B binding pockets.
✕Less likely to help
Patients with lung cancer who do not have the targeted genetic markers or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates a novel vaccination approach for patients with non-small cell lung cancer (NSCLC) that focuses on using their own immune cells, specifically dendritic cells, to enhance the body's immune response against cancer. The study aims to identify specific tumor neoantigens that can trigger a stronger immune reaction, particularly in patients with certain genetic markers. By customizing the vaccine to target these neoepitopes, the goal is to improve the effectiveness of immunotherapy and provide a more personalized treatment option for patients. Participants will receive a vaccination designed to activate their immune system against their cancer cells, potentially leading to better outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for lung cancer patients, improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with dendritic cell-based vaccines in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Garon, Edward B — University of California Los Angeles
- Study coordinator: Garon, Edward B
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.